Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD).

INTRODUCTION: In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti-CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. METHODS: To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of Paediatric Endocrinology and Diabetes (BSPED) Type 1 diabetes Special Interest Group (SIG) and the Association of British Clinical Diabetologists (ABCD) assembled a group to review the clinical trial data and develop expert consensus guidelines on the approach to teplizumab infusions. CONCLUSION: Here, we present recommendations on all aspects of teplizumab administration with evidence base where available. We highlight the safety considerations in individual's selection, screening, monitoring and treatment of potential common side effects.